Announcements
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
- Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
- Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
- Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
- Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
- Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
- Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
- Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.06 |
---|---|
High | 3.06 |
Low | 2.88 |
Bid | 2.76 |
Offer | 2.98 |
Previous close | 3.04 |
Average volume | 0.00 |
---|---|
Shares outstanding | 70.71m |
Free float | 59.40m |
P/E (TTM) | -- |
Market cap | 236.17m USD |
EPS (TTM) | -0.7415 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 18:30 BST.
More ▼